Development and Comparison of a Warfarin-Dosing Algorithm for Korean Patients With Atrial Fibrillation

Clinical Therapeutics

Volumn 33, Issue 10, 2011, Pages 1371-1380

  Cho, Hyun Jung ^a   On, Young Keun ^b   Bang, Oh Young ^b   Kim, Jong Won ^b   Huh, Wooseong ^b   Ko, Jae Wook ^b   Kim, June Soo ^b   Lee, Soo Youn ^b  

^a Konyang University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Atrial fibrillation; CYP2C9; Korean; VKORC1; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ATORVASTATIN; CARBAMAZEPINE; CYTOCHROME P450 2C9; PHENYTOIN; PITAVASTATIN; PRAVASTATIN; PROTEIN; PROTEIN VKORC1; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; WARFARIN;

ACCURACY; ADULT; ALGORITHM; ARTICLE; BODY SURFACE; BODY WEIGHT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; KOREA; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETIC DOSING ALGORITHM; PHARMACOGENETICS; PREDICTION; PROCESS DEVELOPMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

AGED; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; METABOLIC DETOXICATION, DRUG; MIXED FUNCTION OXYGENASES; MULTIVARIATE ANALYSIS; PHARMACOGENETICS; REGRESSION ANALYSIS; REPUBLIC OF KOREA; WARFARIN;

EID: 80054900314     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.004     Document Type: Article

References (44)

1. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
2. Hart R.G., Halperin J.L. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001, 32:803-808.
3. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:429S-456S.
4. Fuster V., Ryden L.E., Asinger R.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001, 38:1231-1266.
5. Snow V., Weiss K.B., LeFevre M., et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003, 139:1009-1017.
6. Jones M., McEwan P., Morgan C.L., et al. Evaluation of the pattern of treatment level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005, 91:472-477.
7. Linkins L.A., Choi P.T., Douketis J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003, 139:893-900.
8. Wadelius M., Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007, 7:99-111.
9. Furuya H., Fernandez-Salguero P., Gregory W., et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995, 5:389-392.
10. Linder M.W., Looney S., Adams J.E., et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis 2002, 14:227-232.
11. Aquilante C.L., Langaee T.Y., Lopez L.M., et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006, 79:291-302.
12. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352:2285-2293.
13. Gage B.F., Lesko L.J. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008, 25:45-51.
14. Van Schie R.M., Wadelius M.I., Kamali F., et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009, 10:1687-1695.
15. Accessed June 2010. http://www.clinicaltrials.gov.
16. COAG Research Network Accessed June 2010. http://coagstudy.org.
17. Wen M.S., Lee M., Chen J.J., et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008, 84:83-89.
18. Takahashi H., Wilkinson G.R., Nutescu E.A., et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006, 16:101-110.
19. Gage B.F., Eby C., Johnson J.A., et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008, 84:326-331.
20. Yoshizawa M., Hayashi H., Tashiro Y., et al. Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. Thromb Res 2009, 124:161-166.
21. Zhu Y., Shennan M., Reynolds K.K., et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 2007, 53:1199-1205.
22. Kim H.S., Lee S.S., Oh M., et al. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenet Genomics 2009, 19:103-112.
23. Klein T.E., Altman R.B., Eriksson N., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360:753-764.
24. Perini J.A., Struchiner C.J., Silva-Assuncao E., et al. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther 2008, 84:722-728.
25. Sconce E.A., Khan T.I., Wynne H.A., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005, 106:2329-2333.
26. Wadelius M., Chen L.Y., Lindh J.D., et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113:784-792.
27. Wu A.H., Wang P., Smith A., et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008, 9:169-178.
28. Huang S.W., Chen H.S., Wang X.Q., et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009, 19:226-234.
29. Cho H.J., Sohn K.H., Park H.M., et al. Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 2007, 8:329-337.
30. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e257-e354.
31. Currie C.J., Jones M., Goodfellow J., et al. Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart 2006, 92:196-200.
32. Andersen L.V., Vestergaard P., Deichgraeber P., et al. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart 2008, 94:1607-1613.
33. Gage B.F., Eby C., Milligan P.E., et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004, 91:87-94.
34. Borgiani P., Ciccacci C., Forte V., et al. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 2007, 8:1545-1550.
35. Cooper G.M., Johnson J.A., Langaee T.Y., et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008, 112:1022-1027.
36. Millican E.A., Lenzini P.A., Milligan P.E., et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007, 110:1511-1515.
37. Lenzini P., Wadelius M., Kimmel S., et al. Integration of genetic, clinical and INR data to refine warfarin dosing. Clin Pharmacol Ther 2010, 87:572-578.
38. Li C., Schwarz U.I., Ritchie M.D., et al. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2009, 113:3925-3930.
39. Michaud V., Vanier M.C., Brouillette D., et al. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin Pharmacol Ther 2008, 83:740-748.
40. Ferder N.S., Eby C.S., Deych E., et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 2010, 8:95-100.
41. Rose J.P., Rihn T.L., Long S.F. Warfarin sensitivity after mechanical heart valve replacement. Pharmacotherapy 1998, 18:856-859.
42. Ageno W., Turpie A.G. Exaggerated initial response to warfarin following heart valve replacement. Am J Cardiol 1999, 84:905-908.
43. Sconce E.A., Daly A.K., Khan T.I., et al. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet Genomics 2006, 16:609-611.
44. Caldwell M.D., Awad T., Johnson J.A., et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008, 111:4106-4112.